We herein present an overview of the upcoming 5 th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …

The upcoming 5th edition of the World Health Organization (WHO) Classification of
Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in …

Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in
terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is …

THE receptor tyrosine kinase Flk-1 (ref. 1) is believed to play a pivotal role in endothelial
development. Expression of the Flk-1 receptor is restricted to endothelial cells and their …

Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma
(SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are …

Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often
have coexisting conditions in addition to disease-related immunosuppression and …

Background Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive
T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) …

In acute myeloid leukaemia (AML), the cell of origin, nature and biological consequences of
initiating lesions, and order of subsequent mutations remain poorly understood, as AML is …

This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and
safety vs conventional care regimens (CCRs) in 488 patients age ≥65 years with newly …

Background Irreversible inhibition of Bruton’s tyrosine kinase (BTK) by ibrutinib represents
an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). …